このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

地域ベースのリハビリテーションを通じてマラウイの精神病患者のメンタルヘルスの成果を向上 (ENHANCE)

2026年8月28日 更新者:University of North Carolina, Chapel Hill

看護師による地域ベースのリハビリテーションを通じて、マラウイの精神病患者の急性期後の精神的健康改善:ENHANCEパイロット試験

The overall aim of the proposed study is to determine the feasibility, acceptability, fidelity, and preliminary effectiveness of the adapted nurse-led, community-based rehabilitation treatment model for community-dwelling individuals living with psychosis in Blantyre, Malawi using a pilot randomized controlled trial.

調査の概要

詳細な説明

Psychosis exacts a heavy morbidity and mortality toll worldwide, but especially in low- and middle-income countries (LMICs). Psychotic disorders are one of the most common presenting complaints for individuals admitted to specialty mental health services in many LMICs. Psychotic disorders typically have onset in early adulthood and a chronic course, meaning patients suffer from many years of poor functionality, disability, and lost productivity. Indeed, psychotic disorders remain among the 15 leading causes of disability globally. The chronicity and severity of psychotic disorders exert a heavy burden on family as relatives frequently have to assume caregiver roles in LMIC where access to formal mental health care is limited.

Despite the significant toll of psychosis in LMICs, treatment options are extremely limited and focus heavily on acute, time-limited inpatient stabilization. This focus fails to consider the demonstrated need for long-term post-acute outpatient treatment and community-based rehabilitation to improve outcomes and prevent relapse. Contextual community factors such as reliable continued access to mental health care, stigma and its negative impact on medication adherence, inadequate support, and family conflict are key risk factors for subsequent relapse upon discharge into the community. Research has recommended the need for community interventions to minimize medication non-adherence and limit relapse and readmission.

Community-based rehabilitation (CBR) directly addresses the need for a concerted approach to post-acute community-based care for people with psychosis in low-resource settings. CBR is a general evidence-based approach for the long-term treatment and support of individuals with a broad range of disabilities in resource-constrained settings that is particularly well suited to address the needs of those with psychosis. CBR aims to improve the quality of life of individuals living with disability by supporting medical care engagement, addressing functional goals, and encouraging social inclusion within their families and communities. CBR is amenable to delivery by a range of personnel and involves collaboration between caregivers, community members, and available public sector services to facilitate the rehabilitation of patients.

Accordingly, in this protocol the investigators will pilot-test an adaptation of the evidence-based Community-Based Rehabilitation (CBR) treatment model specifically to address the needs of community-dwelling individuals with psychosis in Malawi. Specifically, investigators will complete a pilot randomized controlled trial to evaluate the feasibility, acceptability, fidelity, and preliminary effectiveness of the adapted CBR treatment model. This work will provide a critical advance in establishing the evidence base for community-based treatment models for people living with psychosis outside of the context of acute inpatient stabilization so as to enhance rehabilitation, functioning, and quality of life.

研究の種類

介入

入学 (実際)

178

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Blantyre、マラウイ
        • Queen Elizabeth Central Hosptial

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria for PWLE:

  • Current outpatient at Queen Elizabeth Central Hospital psychiatry clinic
  • Age 18 or older
  • Diagnosis of schizophrenia spectrum disorder or clinical presentation of symptoms of hallucinations, delusions or thought disorder that persisted for longer than one month and are accompanied by significant functional impairment
  • Resident in Blantyre District
  • Not planning to relocate out of Blantyre District in next 12 months
  • Has a primary caregiver willing to participate in the study
  • Has current elevated symptoms or poor functioning as demonstrated by one or more of:

Positive and Negative Symptoms Scale score ≥58

WHO Disability Assessment Schedule 2.0 score ≥35

Clinical Global Impression Severity score ≥2 (at least mildly ill)

Inclusion Criteria for Caregivers:

  • Is a current caregiver for an eligible and consenting patient participant.
  • Age 18 or older
  • Resident in Blantyre District
  • Not planning to relocate out of Blantyre District in next 12 months

Exclusion Criteria for PWLE:

  • Not a current outpatient at Queen Elizabeth Central Hospital psychiatry clinic
  • Not Age 18 or older
  • No diagnosis of schizophrenia spectrum disorder or clinical presentation of symptoms of hallucinations, delusions or thought disorder that persisted for longer than one month and are accompanied by significant functional impairment
  • Not a resident in Blantyre District
  • Planning to relocate out of Blantyre District in next 12 months
  • Does not have a primary caregiver willing to participate in the study
  • Does not have current elevated symptoms or poor functioning as demonstrated by one or more of:

Positive and Negative Symptoms Scale score ≥58

WHO Disability Assessment Schedule 2.0 score ≥35

Clinical Global Impression Severity score ≥2 (at least mildly ill)

Exclusion Criteria for Caregivers:

  • Is not a current caregiver for an eligible and consenting patient participant.
  • Not Age 18 or older
  • Not a resident in Blantyre District
  • Planning to relocate out of Blantyre District in next 12 months

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Adapted ENHANCE Intervention

Nurse-delivered community-based treatment model for people living with psychosis in the community, coordinated with the usual outpatient care

Participants randomized to the intervention arm will receive community-based rehabilitation (CBR) delivered by the Queen Elizabeth Central Hospital (QECH) clinical team of psychiatric nurses. The ENHANCE CBR intervention will consist of nurse-delivered home visits over approximately a 12-month period with decreasing intensity, with approximately weekly visits for an initial phase of 2-4 months; biweekly visits for an intermediate phase of 4-6 months; and monthly for a final transition phase of 3-4 months. The exact schedule and duration of each phase will be individualized by the nurse to the participant based on the participant's initial presentation and their response during the intervention. The intervention team will deliver intervention content with the participant and/or family members and caregivers as appropriate to the module.

アクティブコンパレータ:Enhanced usual care

Continue with usual outpatient care, enhanced with additional feedback and clinical recommendations to the outpatient treatment team

Participants randomized to usual care will continue to receive their standard clinical care at Queen Elizabeth Central Hospital (QECH) as previously. The clinical team will be provided a summary of the results of the eligibility assessment, specifically an interpretation of the scores on the symptomatology and disability scales with any relevant clinical recommendations. These individuals will receive no home-based services.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants Approached to Meet Enrollment (Recruitment Feasibility)
時間枠:Baseline

This measure is the ability to successfully enroll people with lived experience (PWLE) in the pilot intervention. Feasibility will be evaluated by measuring the number of participants approached in order to accrue the final sample.

Baseline
Proportion of Participants Retained in the Study (Retention Feasibility)
時間枠:12 months

Feasibility will be evaluated by measuring the proportion of participants retained in the study (participants enrolled at baseline who are still enrolled in the trial through 12 months).

12 months
Number of Participants Who Found the Intervention Helpful (Intervention Acceptability)
時間枠:Conclusion of study, Month 12

A subset of intervention participants were asked if they were willing to participate in a qualitative interview. The 12 who agreed to participant were asked a series of qualitative questions including whether or not the intervention was helpful or unhelpful as a measure of satisfaction to inform intervention acceptability. The number indicating "helpful" as their response are reported.

Conclusion of study, Month 12
Number of Intervention Participants Who Completed All Intervention Phases (Intervention Attendance Fidelity)
時間枠:12 months

The total number of participants who completed all three intervention phases, out of the number of all intervention participants. This outcome does not apply to Enhanced Usual Care and no data were collected.

12 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Overall Functioning
時間枠:12 months

Level of functioning will be evaluated using the World Health Organization Disability Assessment Schedule (WHODAS 2.0 12-item version). The WHODAS 2.0 measures general disability related to multiple domains (i.e., understanding and communicating, getting around, self care, getting along with people, life activities, work/school, participation in society). Total scores on each item range from 1 (no disability) to 5 (extreme/cannot do), with higher scores indicating more impairment. Total scores on the scale range from 12 to 60, with higher scores indicating more impairment.

12 months
Quality of Life Based on Short-Form 8 Measure
時間枠:12 months

Quality of life will be evaluated using the Short Form-8 (SF-8). The SF-8 is a shorter, 8-item questionnaire that covers the same eight domains as the full SF-36. The 8 items are scored using normed scoring that ranges from 0 to 100, with higher scores indicative of better quality of life.

12 months
Change in PANSS Total Score From Baseline
時間枠:Baseline,12 months

Change in psychosis symptoms from baseline were evaluated using the Positive and Negative Symptoms Scale total scores (PANSS). Total scores range from 30 to 210 and include the total sum of all three sub-scales, with higher scores indicating worse outcomes. Scores reported are the change in symptoms relative to baseline.

Baseline,12 months
Psychosis Symptom Response
時間枠:12 months

Psychosis symptom response will be defined as the number of participants with a ≥20% reduction in symptoms from baseline as measured using the Positive and Negative Symptoms Scale (PANSS) total score. Total scores range from 30 to 210 and include a sum of all three sub-scales, with higher scores indicating worse outcomes.

12 months
Psychosis Symptom Remission
時間枠:12 months

Psychosis symptom remission was evaluated using the Positive and Negative Symptoms Scale (PANSS). Each PANSS item was scored on a scale from 1 to 7 with 1 = "absent" and and 7 = "extreme" with higher values indicating worse symptoms. Remission was defined as the number of participants who responded as having absent or minimal symptoms on items G5, G9, N1, N4, N6, and P1-3 in the PANSS.

12 months
Clinical Improvement
時間枠:12 months

Clinical improvement will be evaluated using the Clinical Global Impression-Improvement score (CGI-I). Clinical improvement will be measured as the number of participants with a score of 1 ("very much improved") or 2 ("much improved"). The CGI-I is a 1-7 scale, designed to evaluate improvement through a comparison with the initial assessment of the patient at baseline. Possible ratings range from "very much improved" (score of 1) to "very much worse" (score of 7).

12 months
Internalized Stigma
時間枠:12 months

Internalized stigma will be evaluated using the Internalized Stigma of Mental Illness Inventory (ISMI). A total score is calculated by taking a sum of the responses on the items (range=10 to 40). Higher total scores indicate greater internalized stigma.

12 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Brian Pence, PhD, MPH、University of North Carolina, Chapel Hill

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年12月4日

一次修了 (実際)

2025年8月31日

研究の完了 (実際)

2025年8月31日

試験登録日

最初に提出

2023年10月6日

QC基準を満たした最初の提出物

2023年10月6日

最初の投稿 (実際)

2023年10月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月24日

QC基準を満たした最後の更新が送信されました

2026年8月28日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 23-1665
  • R34MH131234 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with the University of North Carolina at Chapel Hill (UNC).

IPD 共有時間枠

9 to 36 months following publication

IPD 共有アクセス基準

The investigator who proposes to use the data has approval from an IRB, IEC, or REB, as applicable, and an executed data use/sharing agreement with UNC.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する